Silke B
Department of Therapeutics and Pharmacology, Queen's University of Belfast, Northern Ireland.
Cardiovasc Drugs Ther. 1993 Jan;7 Suppl 1:45-53. doi: 10.1007/BF00877957.
In chronic heart failure diuretic drugs improve central hemodynamic variables and cardiac pumping secondary to altered plasma and extracellular volumes; humoral markers of these changes include increased plasma renin and aldosterone levels. The latter increases are maximal over the first week but decline with chronic therapy. The plasma alpha-ANP levels show a reciprocal effect; these data are compatible with a rapid contraction of the plasma volume which is sustained during chronic therapy. The acute hemodynamic actions of diuretic agents reflect both immediate and direct vascular actions and also effects secondary to diuresis (volume redistribution). At rest substantial reductions in pulmonary "wedge" pressure (-29%), with a consequent fall in cardiac output (-10%), are described. Total systemic vascular resistance initially increases but "reverse autoregulation" over subsequent weeks returns this elevation gradually towards control values. Tolerance to these initial hemodynamic effects does not occur with maintained therapy; moreover, echocardiographic markers of contractility and exercise capacity may increase. The early venodilator effects of diuretic drugs can be attributed to prostaglandin release and the initial pressor actions to activation of the renin angiotensin system; these vascular actions may have limited relevance to long-term beneficial effects on hemodynamics. Direct pulmonary vasodilation and improved pulmonary compliance remain an interesting finding. Although most patients are both symptomatically and hemodynamically improved at rest, the actions during exercise are more varied. Some individuals with severely impaired left ventricular function show little hemodynamic improvement, whereas those with milder dysfunction usually benefit; in the main this is probably related to the latter being on a steeper cardiac function curve.(ABSTRACT TRUNCATED AT 250 WORDS)
在慢性心力衰竭中,利尿药可改善中心血流动力学变量,并因血浆和细胞外液量改变而改善心脏泵血功能;这些变化的体液标志物包括血浆肾素和醛固酮水平升高。后者的升高在第一周达到最大值,但在长期治疗中会下降。血浆α-心钠素水平呈现相反的效应;这些数据与血浆容量的快速收缩相一致,这种收缩在长期治疗中持续存在。利尿药的急性血流动力学作用既反映了即时和直接的血管作用,也反映了利尿继发的作用(容量重新分布)。据描述,静息时肺“楔压”大幅降低(-29%),随之心输出量下降(-10%)。总全身血管阻力最初增加,但在随后几周的“反向自动调节”使这种升高逐渐恢复到对照值。维持治疗不会产生对这些初始血流动力学效应的耐受性;此外,收缩性和运动能力的超声心动图标志物可能会增加。利尿药早期的静脉扩张作用可归因于前列腺素释放,而初始的升压作用可归因于肾素-血管紧张素系统的激活;这些血管作用可能与对血流动力学的长期有益作用关系有限。直接的肺血管扩张和肺顺应性改善仍是一个有趣的发现。尽管大多数患者在静息时症状和血流动力学均有改善,但运动时的作用则更为多样。一些左心室功能严重受损的个体血流动力学改善甚微,而那些功能障碍较轻的个体通常受益;总体而言,这可能主要与后者处于更陡峭的心脏功能曲线上有关。(摘要截短至250字)